Enhanced mucosal administration of neuroprotective peptides
AssigneeNastech Pharmaceutical Company Inc.
InventorHenry Costantino
Life of this patent
Estimating the term…
Abstract
A formulation for intranasal delivery of a neuroprotective peptide, comprising an aqueous mixture of a peptide having the sequence NAPVSIPQ or a pharmaceutically acceptable salt thereof, a solubilizing agent, a chelator, and a surface active agent. The formulation can contain a peptide salt or mucosal delivery-enhancing agent which increases the amount of neuroprotective peptide reaching the therapeutic target.
Claims21
A pharmaceutical formulation for intranasal delivery of neuroprotective peptide, comprising an aqueous mixture of NAP (SEQ ID NO:
- 1) or a pharmaceutically acceptable salt thereof, a solubilizing agent, a chelator, and a surface active agent.
A pharmaceutical formulation for intranasal delivery of a NAP comprising an aqueous mixture of NAP (SEQ ID NO:
- 1) or a pharmaceutically acceptable salt thereof and at least one mucosal delivery-enhancing agent which increases the bioavailability of NAP by at least about two-fold compared to an aqueous solution formulation of NAP without the mucosal delivery-enhancing agent.
A non-sterile pharmaceutical formulation for intranasal delivery of NAP comprising NAP (SEQ ID NO:
- 1) or a pharmaceutically acceptable salt thereof, methyl-β-cyclodextrin, L-α-phosphatidylcholine didecanoyl and water.
A pharmaceutical formulation for intranasal delivery of a NAP comprising an aqueous mixture of a pharmaceutically acceptable salt of NAP (SEQ ID NO:
- 1) and at least one mucosal delivery-enhancing agent wherein the solubility of NAP is increased by at least about two-fold compared to an aqueous solution formulation of NAP as a free base.
Dependencies are inferred from the claim text.